XML 69 R38.htm IDEA: XBRL DOCUMENT
v3.21.1

Collaborative and Other Relationships (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summary of Activity Related to BAN2401 and Elenbecestat Collaboration |
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2021 |  | 2020 |  |  |  |
Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat |  | $ | 55.5 |  |  | $ | 43.5 |  |  |  |  |
Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income |  | 27.7 |  |  | 21.8 |  |  |  |  |
Total sales and marketing expense incurred by the BAN2401 collaboration |  | 5.7 |  |  | 4.9 |  |  |  |  |
Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income |  | 2.9 |  |  | 2.4 |  |  |  |  |
Summary of Activity Related to Aducanumab Collaboration | A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2021 |  | 2020 |  |  |  |
Total aducanumab development expense |  | $ | 47.0 |  |  | $ | 19.1 |  |  |  |  |
Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income |  | 25.8 |  |  | 10.5 |  |  |  |  |
Total aducanumab sales and marketing expense incurred by the Aducanumab Collaboration Agreement |  | 111.8 |  |  | 22.7 |  |  |  |  |
Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income |  | 60.3 |  |  | 12.3 |  |  |  |  |

X
- Definition [Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration